Hypercoagulability in cirrhosis: causes and consequences 1

@article{Tripodi2011HypercoagulabilityIC,
  title={Hypercoagulability in cirrhosis: causes and consequences 1},
  author={Armando Tripodi and Quentin Mark Anstee and Kirstine K. S{\o}gaard and Massimo Primignani and Dominique Valla},
  journal={Journal of Thrombosis and Haemostasis},
  year={2011},
  volume={9}
}
Summary.  Decreased levels of most coagulation factors and thrombocytopenia are the main haemostatic abnormalities of cirrhosis. As a consequence, this condition was, until recently, considered as the prototype acquired coagulopathy responsible for bleeding. However, recent evidence suggests that it should, rather, be regarded as a condition associated with normal or even increased thrombin generation. The bleeding events that occur in these patients should, therefore, be explained by the… 
View on Wiley
williams.medicine.wisc.edu
232 Citations
Highly Influential Citations
9
Background Citations
81
Methods Citations
4
Results Citations
3

232 Citations

Citation Type

Citation Type

Liver Disease and Hemostatic (Dys)function.
  • A. Tripodi
  • Medicine
    Seminars in thrombosis and hemostasis
  • 2015
TLDR
The earlier considerations have been instrumental to help dismantle the old paradigms of cirrhosis as the epitome of the acquired hemorrhagic coagulopathies and the traditional coagulation tests PT and aPTT as suitable predictors of bleeding risk.
Should We Be Concerned About Coagulation in the Treatment of Acute Variceal Hemorrhage
TLDR
It is concluded that the bleeding events observed in patient with Cirrhosis are likely due to the underlying conditions associated with cirrhosis rather than to the hemostasis derangement, and the common practice of screening patients with traditional coagulation tests and the correction of their abnormalities should be reconsidered.
Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis.
Advances of knowledge on coagulation disorders in liver cirrhosis and their clinical consequences
TLDR
An update of knowledge on the pathophysiology of coagulation and fibrinolysis in liver cirrhosis, the ways of exploring them, their prophylactic and therapeutic consequences and a review based on publication in PubMed from 1995 up to now are presented.
Hemostatic Dysfunction in Liver Diseases.
TLDR
This issue of Seminars in Thrombosis and Hemostasis contains several articles on the pathophysiology and clinical management of the coagulopathy of liver diseases by prominent investigators in this field, and is aimed at providing readers with updated information on this important clinical field.
Antithrombotic Treatment in Cirrhosis
TLDR
The current insights on the role of old and new anticoagulants in cirrhosis are summarized including the clinical implications for management of these patients.
Advances of knowledge on coagulation disorders in liver cirrhosis and their clinical consequences.
TLDR
An update of knowledge on the pathophysiology of coagulation and fibrinolysis in liver cirrhosis, the ways of exploring them, their prophylactic and therapeutic consequences are presented and it is recommended to reduce thrombin generation to reduce the thrombotic events and the rate of liver fibrosis progression.
Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment
TLDR
Anticoagulation therapy, given to patients with cirrhosis of intermediate severity before PVT occurrence, appears to decrease decompensation and mortality rate, and the room for anticoagulations therapy is probably larger than previously recognized, and may be of particular benefit in patients without portal vein thrombosis.
Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management
TLDR
The epidemiology of thromboses related to end-stage liver disease (ESLD), causes of hypercoagulability, describe susceptible populations, and critically evaluate proposed prophylaxis and treatment of thROMboses are analyzed.
Haemostatic balance in cirrhosis
TLDR
The aim of this study was to evaluate the haemostatic balance in cirrhotic patients through assessing the variation of pro- and anticoagulant factors and evaluating the in-vitro thrombin generation in patients with cirrhosis and in healthy patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 130 REFERENCES
Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management
TLDR
An overview of the coagulation system in liver disease is presented with emphasis on the limitations of theCurrent clinical paradigm and the need for a critical re‐evaluation of the current tenets governing clinical practice.
Venous thromboembolism in chronic liver disease.
TLDR
Growing evidence now suggests that a procoagulant state may be also associated with CLD, so that patients with chronic liver disease, irrespective of its etiology, rather than be "naturally anticoagulated" might also experience a large spectrum of spontaneous or unprovoked venous thrombotic complications.
Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests
TLDR
The findings help clarify the pathophysiology of hemostasis in cirrhosis, suggesting that bleeding is mainly due to the presence of hemodynamic alterations and that conventional coagulation tests are unlikely to reflect the coagulated status of these patients.
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
TLDR
High elevated levels of VWF in patients with cirrhosis contribute to the induction of primary hemostasis despite reduced functional properties of the molecule, which might compensate for defects in platelet number and function.
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method
TLDR
The hypercoagulability of plasma from patients with cirrhosis can be detected with the new assay, which compares favorably with the other markers of hypercoAGulability.
Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing
TLDR
Thrombin generation assays are more suitable than PT and APTT for use in acquired coagulation defects, because of their design, which are responsive to thrombin generated as a function of pro‐coagulants, but much less to Thrombin inhibited by the anti‐coAGulants.
Enhanced thrombin generation in patients with cirrhosis‐induced coagulopathy
TLDR
Despite a raised INR, TG parameters are consistent with a hypercoagulable profile in cirrhosis‐related coagulopathy, confirming that the PT or INR should not be used to assess bleeding risk in these patients, and other parameters, such as TG, need to be explored as clinical markers of coagULopathy.
Thrombin generation in patients with cirrhosis: The role of platelets
TLDR
Severe thrombocytopenia may limit thrombin generation in patients with cirrhosis, and these findings might justify platelet transfusion in Patients with low platelet counts when they bleed spontaneously or before undergoing surgery or liver biopsy.
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis.
TLDR
The hypercoagulability of plasma from patients with cirrhosis appears to result from increased levels of factor VIII and decreased levels of protein C-typical features of patients with Cirrhosis, which might explain the risk for venous thromboembolism in patients with chronic liver disease.
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C
TLDR
It was shown that when ALT activity was measured on the same blood sample in nine different laboratories, interlaboratory variability was high when the result was expressed as upper limit of normal, with some laboratories considering it normal and others high, while this variability was significantly reduced when expressed as IU/L.
...
1
2
3
4
5
...